Maven Securities LTD increased its position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating) by 35.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 86,638 shares of the biopharmaceutical company's stock after purchasing an additional 22,802 shares during the quarter. Maven Securities LTD owned approximately 0.12% of ChemoCentryx worth $2,172,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas boosted its holdings in ChemoCentryx by 9.2% during the first quarter. Teacher Retirement System of Texas now owns 9,999 shares of the biopharmaceutical company's stock worth $251,000 after purchasing an additional 841 shares during the last quarter. Swiss National Bank raised its position in ChemoCentryx by 0.8% in the fourth quarter. Swiss National Bank now owns 107,700 shares of the biopharmaceutical company's stock worth $3,921,000 after acquiring an additional 900 shares during the period. UMB Bank N A MO bought a new stake in ChemoCentryx in the fourth quarter worth about $37,000. Level Four Advisory Services LLC raised its position in ChemoCentryx by 10.9% in the first quarter. Level Four Advisory Services LLC now owns 13,016 shares of the biopharmaceutical company's stock worth $326,000 after acquiring an additional 1,276 shares during the period. Finally, Lazard Asset Management LLC bought a new stake in ChemoCentryx in the fourth quarter worth about $60,000. 81.09% of the stock is currently owned by hedge funds and other institutional investors.
Get
ChemoCentryx alerts:
ChemoCentryx Stock Performance
NASDAQ CCXI opened at $51.49 on Friday. The company's 50 day moving average is $38.44 and its 200-day moving average is $28.44. ChemoCentryx, Inc. has a 12-month low of $14.95 and a 12-month high of $51.78. The company has a quick ratio of 4.47, a current ratio of 4.54 and a debt-to-equity ratio of 0.02. The firm has a market cap of $3.67 billion, a P/E ratio of -27.24 and a beta of 1.25.
Analyst Upgrades and Downgrades
Several analysts have commented on CCXI shares. HC Wainwright lowered shares of ChemoCentryx from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $101.00 to $52.00 in a research report on Friday, August 5th. StockNews.com raised shares of ChemoCentryx from a "sell" rating to a "hold" rating in a research report on Wednesday, August 10th. SVB Leerink lowered shares of ChemoCentryx from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $64.00 to $52.00 in a research report on Friday, August 5th. Canaccord Genuity Group started coverage on shares of ChemoCentryx in a research report on Thursday, August 4th. They issued a "buy" rating and a $81.00 price objective on the stock. Finally, Stifel Nicolaus lowered shares of ChemoCentryx from a "buy" rating to a "hold" rating in a research report on Wednesday, August 10th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, ChemoCentryx currently has a consensus rating of "Hold" and a consensus price target of $65.25.
Insider Activity
In related news, CEO Thomas J. Schall sold 130,000 shares of the company's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now owns 2,393,352 shares of the company's stock, valued at approximately $120,242,004.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director James L. Tyree sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $50.22, for a total transaction of $502,200.00. Following the sale, the director now owns 9,138 shares of the company's stock, valued at approximately $458,910.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas J. Schall sold 130,000 shares of the company's stock in a transaction that occurred on Thursday, August 4th. The stock was sold at an average price of $50.24, for a total transaction of $6,531,200.00. Following the sale, the chief executive officer now directly owns 2,393,352 shares in the company, valued at approximately $120,242,004.48. The disclosure for this sale can be found here. Insiders have sold a total of 213,760 shares of company stock valued at $10,749,838 over the last quarter. Company insiders own 8.30% of the company's stock.
ChemoCentryx Company Profile
(Get Rating)
ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
Read More
- Get a free copy of the StockNews.com research report on ChemoCentryx (CCXI)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx, Inc. (NASDAQ:CCXI – Get Rating).
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.
